全文获取类型
收费全文 | 1625706篇 |
免费 | 136306篇 |
国内免费 | 4573篇 |
专业分类
耳鼻咽喉 | 21810篇 |
儿科学 | 53121篇 |
妇产科学 | 46459篇 |
基础医学 | 230816篇 |
口腔科学 | 47595篇 |
临床医学 | 144554篇 |
内科学 | 318444篇 |
皮肤病学 | 34328篇 |
神经病学 | 131516篇 |
特种医学 | 65924篇 |
外国民族医学 | 492篇 |
外科学 | 246560篇 |
综合类 | 44468篇 |
现状与发展 | 15篇 |
一般理论 | 548篇 |
预防医学 | 124690篇 |
眼科学 | 37136篇 |
药学 | 123979篇 |
37篇 | |
中国医学 | 4661篇 |
肿瘤学 | 89432篇 |
出版年
2018年 | 15809篇 |
2016年 | 13798篇 |
2015年 | 16266篇 |
2014年 | 22278篇 |
2013年 | 32778篇 |
2012年 | 44574篇 |
2011年 | 46914篇 |
2010年 | 27698篇 |
2009年 | 26357篇 |
2008年 | 44263篇 |
2007年 | 46507篇 |
2006年 | 47270篇 |
2005年 | 45846篇 |
2004年 | 44852篇 |
2003年 | 42993篇 |
2002年 | 42033篇 |
2001年 | 76255篇 |
2000年 | 78893篇 |
1999年 | 66955篇 |
1998年 | 18097篇 |
1997年 | 16709篇 |
1996年 | 16555篇 |
1995年 | 16271篇 |
1994年 | 15291篇 |
1993年 | 14360篇 |
1992年 | 55567篇 |
1991年 | 53905篇 |
1990年 | 52633篇 |
1989年 | 50901篇 |
1988年 | 47301篇 |
1987年 | 46614篇 |
1986年 | 44313篇 |
1985年 | 42863篇 |
1984年 | 32049篇 |
1983年 | 27575篇 |
1982年 | 16147篇 |
1981年 | 14444篇 |
1980年 | 13566篇 |
1979年 | 30467篇 |
1978年 | 21067篇 |
1977年 | 17764篇 |
1976年 | 16694篇 |
1975年 | 17574篇 |
1974年 | 21487篇 |
1973年 | 20672篇 |
1972年 | 18855篇 |
1971年 | 17770篇 |
1970年 | 16290篇 |
1969年 | 15268篇 |
1968年 | 13950篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kinase alterations are increasingly recognised as oncogenic drivers in mesenchymal tumours. Infantile fibrosarcoma and the related renal tumour, congenital mesoblastic nephroma, were among the first solid tumours shown to harbour recurrent tyrosine kinase fusions, with the canonical ETV6::NTRK3 fusion identified more than 20 years ago. Although targeted testing has long been used in diagnosis, the advent of more robust sequencing techniques has driven the discovery of kinase alterations in an array of mesenchymal tumours. As our ability to identify these genetic alterations has improved, as has our recognition and understanding of the tumours that harbour these alterations. Specifically, this study will focus upon mesenchymal tumours harbouring NTRK or other kinase alterations, including tumours with an infantile fibrosarcoma-like appearance, spindle cell tumours resembling lipofibromatosis or peripheral nerve sheath tumours and those occurring in adults with a fibrosarcoma-like appearance. As publications describing the histology of these tumours increase so, too, do the variety kinase alterations reported, now including NTRK1/2/3, RET, MET, RAF1, BRAF, ALK, EGFR and ABL1 fusions or alterations. To date, these tumours appear locally aggressive and rarely metastatic, without a clear link between traditional features used in histological grading (e.g. mitotic activity, necrosis) and outcome. However, most of these tumours are amenable to new targeted therapies, making their recognition of both diagnostic and therapeutic import. The goal of this study is to review the clinicopathological features of tumours with NTRK and other tyrosine kinase alterations, discuss the most common differential diagnoses and provide recommendations for molecular confirmation with associated treatment implications. 相似文献
2.
目的 观察结肠癌HCT116细胞健脾消癌方的条件培养液对HUVEC细胞管腔形成的影响,从PI3K/Akt生物轴调控角度探讨其作用机制。方法 培养HCT116细胞,细胞设3组:对照组,健脾消癌方组(加入15%健脾消癌方含药血清)及人参皂苷Rg3组;制备HCT116细胞健脾消癌方条件培养液(分组及制备方法见实验方法),用条件培养液干预HUVEC(脐静脉内皮细胞,Human Umbilical Vein Endothelial Cells),Matrigel基质胶法检测HCT116细胞健脾消癌方条件培养液对HUVEC小管形成的影响。随后采用蛋白免疫印迹法(Western blot)检测各组HCT116细胞磷脂酰肌醇3-激酶(PI3K)、蛋白激酶B(Akt)、p-Akt、VEGF(血管内皮生长因子,Vascular endothelial growth factor)蛋白表达。最后在结肠癌HCT116荷瘤小鼠中验证健脾消癌方对肿瘤生长速度的影响,并经瘤组织VEGF蛋白表达、CD31免疫组化染色检测肿瘤内血管生成情况。结果 模型组HUVEC细胞管腔形成较空白血清组显著增加(P<0.05);健脾消癌方组及人参皂苷Rg3组较模型组HUVEC细胞管腔形成显著减少(P<0.01)。p-Akt和VEGF蛋白表达水平模型组高于空白血清组(P<0.05),健脾消癌方组及人参皂苷Rg3组显著低于模型组(P<0.01);PI3K、Akt蛋白表达量组间差异无统计学意义。与对照组比较,模型组荷瘤小鼠肿瘤体积显著性增大,瘤组织内VEGF表达、CD31阳性面积显著性增加,差异有统计学意义(P<0.05);与模型组比较,健脾消癌方组及人参皂苷Rg3组荷瘤小鼠肿瘤体积显著减小,瘤组织内VEGF表达、CD31阳性面积降低,差异有统计学意义(P<0.05)。结论 健脾消癌方可抑制肿瘤的血管生成和生长,其作用机制可能与PI3K/Akt生物轴调控VEGF表达有关。 相似文献
3.
4.
5.
6.
7.
Qian Zhang Larry D. Mesner Gina M. Calabrese Naomi Dirckx Zhu Li Angela Verardo Qian Yang Robert J. Tower Marie-Claude Faugere Charles R. Farber Thomas L. Clemens 《The Journal of clinical investigation》2021,131(7)
Bone mineral density (BMD) is a highly heritable predictor of osteoporotic fracture. GWAS have identified hundreds of loci influencing BMD, but few have been functionally analyzed. In this study, we show that SNPs within a BMD locus on chromosome 14q32.32 alter splicing and expression of PAR-1a/microtubule affinity regulating kinase 3 (MARK3), a conserved serine/threonine kinase known to regulate bioenergetics, cell division, and polarity. Mice lacking Mark3 either globally or selectively in osteoblasts have increased bone mass at maturity. RNA profiling from Mark3-deficient osteoblasts suggested changes in the expression of components of the Notch signaling pathway. Mark3-deficient osteoblasts exhibited greater matrix mineralization compared with controls that was accompanied by reduced Jag1/Hes1 expression and diminished downstream JNK signaling. Overexpression of Jag1 in Mark3-deficient osteoblasts both in vitro and in vivo normalized mineralization capacity and bone mass, respectively. Together, these findings reveal a mechanism whereby genetically regulated alterations in Mark3 expression perturb cell signaling in osteoblasts to influence bone mass. 相似文献
8.
9.
10.